Mutual of America Capital Management LLC Decreases Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Mutual of America Capital Management LLC trimmed its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 4.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,935 shares of the specialty pharmaceutical company’s stock after selling 1,442 shares during the quarter. Mutual of America Capital Management LLC owned 0.05% of Jazz Pharmaceuticals worth $3,933,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. GW&K Investment Management LLC raised its position in shares of Jazz Pharmaceuticals by 26.6% during the 4th quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company’s stock valued at $57,142,000 after buying an additional 97,589 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $4,762,000. Oppenheimer Asset Management Inc. raised its position in Jazz Pharmaceuticals by 24.2% in the 4th quarter. Oppenheimer Asset Management Inc. now owns 9,588 shares of the specialty pharmaceutical company’s stock worth $1,181,000 after purchasing an additional 1,867 shares during the period. Bank of New York Mellon Corp raised its position in Jazz Pharmaceuticals by 5.4% in the 4th quarter. Bank of New York Mellon Corp now owns 477,751 shares of the specialty pharmaceutical company’s stock worth $58,835,000 after purchasing an additional 24,481 shares during the period. Finally, IFP Advisors Inc purchased a new stake in Jazz Pharmaceuticals in the 4th quarter worth about $25,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on JAZZ shares. Robert W. Baird increased their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. JPMorgan Chase & Co. increased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and increased their price objective for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. Royal Bank of Canada reduced their price objective on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 26th. Finally, Piper Sandler reissued an “overweight” rating and issued a $176.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $182.47.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the sale, the chief executive officer now directly owns 425,525 shares in the company, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Patricia Carr sold 4,813 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the sale, the chief accounting officer now owns 8,237 shares of the company’s stock, valued at approximately $1,189,587.54. This trade represents a 36.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 18,113 shares of company stock worth $2,551,834 over the last three months. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $140.23 on Thursday. The company has a market cap of $8.52 billion, a price-to-earnings ratio of 19.75, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The company has a 50 day moving average of $127.64 and a two-hundred day moving average of $119.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.